re: cce
This news just in from Pattersons Biotech report:
Clinical Cell Culture CCE ($0.37, MCap $82.9m)
▲ Initial recommendation on CCE was based on the belief that marketing approval from the FDA was imminent and would result in a significant re-rating of the stock. While the company continues to provide assurance that approval will be granted by the end of the year, we believe that this may now be factored into CCE’s price.
We also believe that as the impact of some other significant and unexpected positive announcements, such as the early marketing approval of ReCell in Argentina, has been limited, we are no longer expecting a near term re-rating of CCE.
We continue to believe that CCE will provide an attractive speculative investment however the stock will be exposed to any delays the company experiences in generating sales revenues from both its CellSpray and ReCell products.
Means that there is still a chance to buy and sell on the rises and falls as far as I interpret.
CCE Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
